SCHEDULE: Altai Capital Nominates Directors, Slams OraSure Strategy

Activist investor Altai Capital Management, holding 5.2% of OraSure Technologies, announced its intention to nominate two directors to the board, citing a 'failing strategy' and 'destroyed shareholder value'.

Summary

• Altai Capital Management, a beneficial owner of approximately 5.2% of OraSure Technologies' common stock, intends to nominate John Bertrand and Rishi Bajaj for election to the Board at the 2026 Annual Meeting of Stockholders.
• Altai Capital criticizes OraSure's Board for its "failing strategy in life sciences" and "destroyed significant shareholder value."
• Key issues highlighted include management's failure to turn around core product segments, squandering millions on ill-timed venture-like investments, and continued cash burn without tangible returns.
• OraSure's stock has significantly underperformed relevant indices over the past 5 and 10 years.
• The company has squandered 25% of its cash and cash equivalents since Q4 2023, while quarterly revenue (excluding Covid-19 products) declined over 20% in the same period.
• Altai Capital views the recent appointment of Stephen Boyd to the Board as "cosmetic" and lacking relevant experience for a critical turnaround.

Sentiment

Score: 2

Explanation: The filing expresses strong negative sentiment regarding OraSure's current strategy, financial performance, and Board effectiveness. It highlights significant value destruction, cash burn, and underperformance relative to industry benchmarks, indicating a highly critical and urgent call for change from a major shareholder.

Positives

• Activist investor Altai Capital, holding 5.2% of outstanding shares, is actively seeking to drive value creation and mitigate future value destruction.
• The proposed director nominees, John Bertrand and Rishi Bajaj, bring significant executive leadership, healthcare technology, AI, investment management, and public company board experience.

Negatives

• OraSure's Board is "obstinately committed to the Company's failing strategy in life sciences."
• The company has "destroyed significant shareholder value across every reasonable metric."
• Management failed to execute a turnaround of core product segments as Covid-19 windfall revenue declined.
• OraSure "squandered millions of dollars making ill-timed venture-like investments in failing, subscale and/or unprofitable companies."
• The company continues to burn cash in its core product segments with no tangible return on the horizon.
• OraSure's stock performance has significantly underperformed relevant indices over 5 and 10 years.
• The company squandered 25% of its cash and cash equivalents balance since Q4 2023.
• Quarterly revenue (excluding Covid-19 products) declined over 20% in the same timeframe (since Q4 2023).
• The recent Board appointment of Stephen Boyd is criticized for lacking relevant experience and being "cosmetic."

Risks

• Risk of permanent capital impairment will continue to increase if the Board does not change course.
• Little hope that OraSure will outperform relative to its risk under current management.

Future Outlook

Altai Capital believes there is "little hope that OraSure will outperform relative to its risk" under the current Board and management. They propose a "better path forward to transform the Company that will deliver substantial near-term and long-term value to all shareholders while mitigating the potential for future value destruction."

Management Comments

• "The Board remains obstinately committed to the Company's failing strategy in life sciences that has destroyed significant shareholder value across every reasonable metric."
• "The current Board is not capable of taking the necessary steps to transform the Company."
• "Shareholders should not fund Mr. Boyd's education as OraSure attempts to navigate a critical turnaround situation."
• "OraSure has made no meaningfully positive operational or directional changes. It is transparent to us and many other shareholders that these actions are simply cosmetic and are not intended to take real accountability."
• "If the Board does not change course immediately, the risk of permanent capital impairment will continue to increase."
• "We and Mr. Bertrand believe there is a better path forward to transform the Company that will deliver substantial near-term and long-term value to all shareholders while mitigating the potential for future value destruction."

Industry Context

OraSure's performance is significantly lagging behind broader market and healthcare/life science indices. While the broader life science and healthcare sectors have seen substantial growth (e.g., Bloomberg US 3000 Life Science & Diagnostics Price Return Index up 41% over 5 years, S&P 500 Health Care Index up 52% over 5 years), OraSure has experienced significant declines, indicating company-specific issues rather than industry headwinds. The criticism of "ill-timed venture-like investments" suggests a misalignment with prudent capital allocation strategies common in mature life science companies.

Comparison to Industry Standards

• OraSure's 5-year performance (-80% return) significantly underperformed the Bloomberg US 3000 Life Science & Diagnostics Price Return Index (+41%), the S&P 500 Health Care Index (+52%), the NASDAQ Composite Index (+95%), and the NYSE Composite Index (+76%).
• OraSure's 10-year performance (-60% return) also significantly lagged the Bloomberg US 3000 Life Science & Diagnostics Price Return Index (+223%), the S&P 500 Health Care Index (+155%), the NASDAQ Composite Index (+395%), and the NYSE Composite Index (+170%).
• The company's cash burn and revenue decline (25% of cash squandered, 20% ex-Covid revenue decline since Q4 2023) contrast sharply with the growth seen in the broader life science and healthcare sectors.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant value creation if Altai Capital's proposed changes are implemented, or continued value destruction if the current strategy persists. Increased engagement and potential proxy fight.
• Management/Board: Increased pressure and scrutiny from a major activist shareholder, potential for leadership changes.
• Employees: Potential for strategic shifts could impact business units, though not explicitly mentioned.
• Customers/Suppliers: Not directly addressed, but strategic changes could indirectly affect product focus or operational efficiency.

Next Steps

• Altai Capital intends to nominate John Bertrand and Rishi Bajaj for election to the Board at the 2026 Annual Meeting of Stockholders.
• Altai Capital will present its case directly to shareholders if the Board fails to act.
• Altai Capital remains open to engaging with the Board and management to achieve shared long-term goals.

Key Dates

Recommendation

The filing from a significant activist shareholder (5.2%) paints a dire picture of OraSure Technologies, citing a "failing strategy," "destroyed significant shareholder value," substantial cash burn (25% of cash squandered since Q4 2023), and a significant decline in core revenue (over 20% ex-Covid since Q4 2023). The company's stock has drastically underperformed all relevant indices over 5 and 10 years. While the activist's intent to nominate directors offers a glimmer of hope for future change, the current state and trajectory described by Altai Capital suggest severe underlying issues and a high risk of "permanent capital impairment." For a seasoned investor, the immediate outlook based on these disclosures is extremely negative, warranting a strong sell recommendation until there is clear evidence of a fundamental strategic shift and improved financial performance.

Keywords

OraSure Technologies, Altai Capital, Shareholder Activism, Board Nomination, Corporate Governance, Life Sciences, Healthcare Technology, Rishi Bajaj, John Bertrand, Stock Performance, Value Creation, Cash Burn, Strategic Review